OREANDA-NEWS. Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet") today announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its offer to purchase all outstanding shares of common stock of LDR Holding Corporation (NASDAQ: LDRH) ("LDR").

As previously announced, Zimmer Biomet, through its indirect wholly owned subsidiary, LH Merger Sub, Inc., commenced an offer on June 14, 2016 to purchase all of the outstanding shares of common stock of LDR for $37.00 per share, net to the seller in cash. 

The early termination of the waiting period satisfies one of the conditions to the offer, which will expire at 12:00 midnight, New York City time, on July 13, 2016 (one minute after 11:59 p.m., New York City time, on July 12, 2016), unless the offer is extended as described in the Offer to Purchase filed by Zimmer Biomet with the Securities and Exchange Commission on June 14, 2016. The completion of the offer is subject to the tender of a majority of the outstanding shares of common stock of LDR and other customary closing conditions described in such Offer to Purchase. 

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.